Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research

  01 September 2021

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database. The agreement with the United States Army is synergistic with APT’s ongoing partnership with the United States Navy, providing the company with access to the pre-eminent phage database of the United States military to treat critically ill patients.

Further reading: Pipeline Review
Author(s): Pipeline Review
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed